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tivecommons.org/licenses/by-nc-Summary Background and aim: Intrahepatic cholangiocellular carcinoma (ICC) is an uncom-
mon but lethal cancer. The aim of this study is to assess the factors affecting the survival of ICC
patients and to evaluate the benefit of these factors when various therapeutic modalities are
used.
Methods: Between October 2007 and June 2012, 66 ICC cases among 2255 liver cancer patients
were identified by pathology and divided into two groups: Group I (surgery group; nZ 17) and
Group II (nonsurgery group; n Z 49). Group II was further divided into Group IIa (those
receiving palliative treatment; nZ 19) and Group IIb (no treatment received; nZ 30). Factors
affecting patient survival over the study period were assessed (3- and 6-month results were
reported) and therapeutic benefits identified within each of the groups were evaluated.
Results: Of the 66 patients identified (male/female Z 36/30), 10.6% (7/66) were in the early
stages of illness. Overall, the mean patient survival duration was 3.50  0.92 months (1.69
e5.31 months). The mean survival duration of Group I patients was 10.50  2.84 months
(4.94e16.06 months). The mean survival duration of Group II patients was 3.50  0.65 months
(2.24e4.76 months) with Group IIa patients surviving on average 9.50  3.27 months (3.10
e15.90 months) and Group IIb patients surviving on average 1.50  0.12 months (1.26e1.74
months). Better survival outcomes were observed in the groups receiving treatment, Group I
and Group IIa, than in Group Iib, which did not receive treatment [9.50  1.73 months (6.12
e12.89 months) vs. 1.50  0.12 months (1.26e1.74 months), p < 0.001]. Lower albumin, higherepato-Gastroenterology, Department of Internal Medicine, China Medical University Hospital, Number
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12 C.-F. Ting et al.bilirubin, higher CA19-9, advanced tumor stage, and no treatment were identified as important
predictors of patient mortality at the 3- and 6-month time-points. These factors remained
relevant throughout the entire study period (pZ 0.002, 0.029, 0.027, 0.028, < 0.001, respec-
tively).
Conclusion: This study identified surgery as the treatment that provided the best survival prog-
nosis for patients with ICC. Treatment involving either chemotherapy or radiotherapy could
also prolong ICC patient survival. Better liver preservation, lower CA19-9, and less aggressive
tumor conditions were identified as factors which play crucial roles in enhancing patient sur-
vival.
Copyright ª 2015, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society
of Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Cholangiocarcinoma is a relatively uncommon but lethal
cancer of the biliary epithelium; it accounts for 10e25% of
all hepatobiliary malignancies [1,2]. Various risk factors for
cholangiocarcinoma and a number of different diagnostic/
therapeutic modalities have been examined in clinical
scenarios in order to understand the factors affecting sur-
vival of patients with this disease. To date a satisfactory
solution to this global problem has not been found. At-
tempts to identify the factors affecting patient survival
have been impeded by: (1) a lack of disease-specific
symptoms in early stages; (2) surgical resection not being
an appropriate treatment option; and (3) high rates of
tumor recurrence following surgical resection [3e9].
According to anatomic locations, cholangiocarcinoma is
classified into three subtypes, including: (1) intrahepatic
cholangiocarcinoma (ICC); (2) perihilar cholangiocarcinoma
(PCC); and (3) distal cholangiocarcinoma (DCC) [8]. Results
from a large, single-centered study found that ICC
accounted for less than 10% of cases of chol-
angiocarcinoma; PCC for 50%; and DCC for approximately
40% [10]. In contrast to PCC and DCC, the incidence of ICC
saw a steady increase of 22% between 1979 and 2004 due to
advances in diagnostic techniques in Western countries
[6,11,12]. This increase in incidence was accompanied by a
39% increase in mortality [12]. ICC has overtaken hepato-
cellular carcinoma (HCC) as the leading cause of death in
the UK since the mid-1990s [13]. Previous studies describe
the distinction between ICC and extrahepatic chol-
angiocarcinoma [14], but potential risk factors remain un-
known [2]. Therefore, establishing the prognostic factors
and locations of tumor involvement such as peripheral or
main bile ducts or extrahepatic metastasis may decide the
patient’s prognosis prior to implementation of intervention
options.
To attain the greatest benefit in clinical scenarios, two
points were assessed in this study. First the predictive
factors affecting survival over the study period (including
3- and 6-month results) were investigated. These factors
were then used to further elucidate the benefits of various
modalities, which included curative, palliative, and no
treatment, in ICC patients. We expect this study to provide
valuable information which can be used in clinical
settings.Patients and methods
Patients
Between October 2007 and June 2012, 2255 patients with
liver cancer were identified at China Medical University
Hospital, Taichung, Taiwan. Well-characterized clinical
data were recorded for all patients: e.g., liver function,
renal function, hematological examination, and tumor
markers. Tumor staging was based on abdominal comput-
erized tomography and confirmed histopathology by pa-
thologists. After exclusion criteria were applied, 66 ICC
patients with positive pathology were enrolled in this study;
their clinical results were recorded until July 2014. The
exclusion criteria included patients with hepatocellular
carcinoma (HCC), combined HCC with cholangiocarcinoma,
secondary tumors, and cholangiocarcinoma subtypes PCC
and ICC.
Definition
ICC is a cholangiocarcinoma subtype affecting the intra-
hepatic biliary tract and classification of tumor involvement
is made according to the American Joint Committee on
Cancer (AJCC) TNM (tumor, node, and metastases) Staging
System [15]. According to initial therapy, therapeutic mo-
dalities were classified into three groups which were Group
I, Group IIa and Group IIb. Group I (surgery group) included
patients with potentially resectable tumors according to
standard operative approach [16]; Group II (nonsurgery
group) included patients with unresectable tumors. Group II
was further divided into two sub-groups: Group IIa (pallia-
tive treatment) which included patients treated by
chemotherapy (e.g., cisplatin, gemcitabine, fluorouracil,
leucovorin) or radiotherapy, and Group IIb (no treatment)
which included patients receiving either palliative biliary
drainage or no treatment.
Serological virus markers and liver biochemical
assays
Commercial enzyme immunoassay rated HBV (hepatitis B
virus) markers (HBsAg, anti-HBs, HBeAg, anti-HBe) (AxSYM,
Abbott, North Chicago, IL, USA) and anti-HCV (hepatitis C
Prognostic factors in intrahepatic cholangiocarcinoma patients 13virus) antibody (Abbott HCV EIA 2.0; Abbott Laboratories;
Cobas Amplicor HCV Monitor 2.0; Roche Diagnostics;
Branchburg, NJ). An autoanalyzer (TBAe30FR, Toshiba,
Tokyo, Japan) gauged serum albumin, bilirubin, a-feto-
protein (AFP), carcinoembryonic antigen (CEA), carbohy-
drate antigen 19-9 (CA19-9), aspartate transaminase (AST),
alanine transaminase (ALT), alkaline phosphatase (ALP), g-
glutamyltransferase (GGT), creatinine, International
Normalize Ratio (INR), and hematological count (WBC:
white blood cell; Hb, hemoglobin; platelet).
Statistical analysis
Baseline data were expressed as mean  standard deviation
(Table 1), variables correlation in 3- or 6-month mortality
was assessed using Student t test or Fisher’s exact test. In
univariate survival analysis, the median survival times were
calculated according to the Kaplan-Meier method. All var-
iables significant in univariate analysis were entered into
the multivariate model according to Cox proportional haz-
ard regression. All statistical tests were two-tailed;
p < 0.05 was defined as significant.
Results
Among 2255 patients, 66 ICC cases (66/2255 Z 2.93%)
were confirmed by liver biopsy or resection, including 36Table 1 Baseline characteristics of intrahepatic chol-
angiocarcinoma (ICC) patients (N Z 66).
Demographics
Age (y) (range) 64.55  12.16 (35.00e87.00)
Sex (male) (%) 36 (54.5%)
HBV/HCV/NBNC (%) 18 (27.3%)/6 (9.1%)/42 (63.6%)
Cirrhosis (þ) (%) 5 (7.6%)
TNM stage
(I/II/III/IV) (%)
7 (10.6%)/8 (12.1%)/
25 (37.9%)/26 (39.4%)
Biochemical values
Albumin (g/dL) 3.63  0.67 (2.00e4.80)
Bilirubin (mg/dL) 2.49  5.17 (0.32e27.93)
Creatinine (mg/dL) 1.02  0.60 (0.51e3.91)
AST (IU/L) 59.47  74.51 (14.00e476.00)
ALT (IU/L) 47.62  54.38 (10.00e269.00)
Alk-p (IU/L) 155.66  126.64 (36.00e654.00)
GGT (IU/L) 198.63  189.42 (13.00e727.00)
WBC (103/dL) 9.94  4.98 (3.99e40.51)
Hb (gm/dL) 12.41  2.17 (8.00e17.00)
Platelet (103/mL) 227.82  86.38 (48.00e520.00)
INR 1.10  0.15 (0.91e1.64)
AFP (ng/mL) 203.29  1445.73 (0.98e11197.00)
CEA (ng/mL) 83.99  381.31 (0.72e2813.69)
CA 19-9 (ng/mL) 5232.09  8025.21
(0.80e22660.00)
AFP Z alphafetaprotein; Alk-p Z alkaline phosphatase;
ALT Z alanine Transaminase; AST Z aspartate transaminase;
B Z hepatitis B virus; C Z hepatitis C virus; CA 19-
9 Z carbohydrate antigen 19-9; CEA Z carbohydrate antigen;
GGT Z g-glutamyltransferase; Hb Z hemoglobin;
INRZ International Normalize Ratio; NBNCZ nonhepatitis B or
C virus; WBC Z white blood cell.males and 30 females with a mean age of 64.55 years
(range: 35.00e87.00 years). Table 1 shows the baseline
characteristics of 66 cases, only 10.6% (7/66) belong to
curative candidates. According to therapeutic modalities,
17 cases accepted surgery (Group I) and 49 cases accepted
nonsurgery (Group II) including 19 cases with palliative
treatment (Group IIa) and 30 cases without treatment
(Group IIb) (Fig. 1). The median overall duration of pa-
tients’ survival was 3.50  0.92 months (1.69e5.31
months). The median duration of patients’ survival in
Group I was 10.50  2.84 months (4.94e16.06 months);
and 3.50  0.65 months (2.24e4.76 months) in Group II
including Group IIa: 9.50  3.27 months (3.10e15.90
months) and Group IIb: 1.50  0.12 months (1.26e1.74
months).
Over the study period, factors including: advanced
tumor stage (III þ IV vs. I þ II, p Z 0.020); no treatment
(p < 0.001); lower albumin (p Z 0.020); higher bilirubin
(p < 0.001); higher GGT (p Z 0.008); higher WBC
(p Z 0.006); and higher CA19-9 (p Z 0.001) presented a
significant impact on patient’s survival according to the
Kaplan-Meier method. Of these factors advanced tumor
stage (hazard ratio Z 2.380, p Z 0.028); no treatment
(hazard ratio Z 9.552, p < 0.001); lower albumin (hazard
ratio Z 4.093, p Z 0.002); higher bilirubin (hazard
ratio Z 2.390, p Z 0.029); and higher CA19-9 (hazard
ratio Z 2.091, p Z 0.027) were independent predictors of
patient mortality (Table 2).
Analyzing 3- and 6-month therapeutic outcomes, mor-
tality (n Z 24) versus survival group (n Z 42) at 3-month
analysis were significant for: the no treatment group (20/
30 vs. 4/36, p < 0.001); lower albumin (3.27  0.58 vs.
3.82  0.65, p Z 0.001); higher bilirubin (4.50  7.80 vs.
1.39  2.37, pZ 0.019); poorer renal function (1.25  0.85
vs. 0.88  0.35, p Z 0.016); higher INR (1.16  0.17 vs.
1.07  0.12, p Z 0.019); and higher CA19-9
(9549.74  9863.11 vs. 3125.92  6396.25, p Z 0.013).
Similarly at the 6-month analysis, mortality (nZ 36) versus
survival group (n Z 30) presented significantly higher male
rate (26/36 vs. 10/30, p Z 0.003); advanced tumor stage
(TNM stage III þ IV vs. I þ II: 32/51 vs. 4/15, pZ 0.019); no
treatment (25/30 vs. 11/36, p < 0.001); lower albumin
(3.43  0.58 vs. 3.87  0.70, p Z 0.008); poorer renal
function (1.14  0.71 vs. 0.86  0.40, pZ 0.048); and high
CA19-9 (7349.11  9241.72 vs. 3044.50  6418.58,
p Z 0.039) (Table S1).Figure 1 Flow diagram showing the initial therapeutic mo-
dalities of all 66 patients over the study period.
Table 2 Cox regression analysis of survival in intrahepatic cholangiocarcinoma (ICC) patients (N Z 66).
Numbers p Hazard ratio (95% CI)
Univariate Multivariate
Demographics
Age (y), 60 vs. >60 25 vs. 41 0.507
Sex, female vs. male 30 vs. 36 0.317
HBV or HCV, () vs. (þ) 42 vs. 24 0.603
Cirrhosis, () vs. (þ) 61 vs. 5 0.464
TNM stage, (IIIþIV) vs. (IþII) 51 vs. 15 0.020* 0.028* 2.380 (1.098e5.160)
Treatment, () vs. (þ) 30 vs. 36 <0.001* <0.001* 9.552 (3.673e24.842)
Biochemical values
Albumin (g/dL), 3.5 vs. >3.5 26 vs. 40 0.020* 0.002* 4.093 (1.706e9.819)
Bilirubin (mg/dL), 1.5 vs.>1.5 51 vs. 15 <0.001* 0.029* 2.390 (1.095e5.219)
Creatinine (mg/dL), 1.3 vs.>1.3 58 vs. 8 0.243
AST (IU/L), 34 vs. >34 31 vs. 35 0.069
ALT (IU/L), 40 vs. >40 47 vs.19 0.676
Alk-p (IU/L), 126 vs. >126 36 vs.29 0.058
GGT (IU/L), 50 vs.> 50 35 vs.29 0.008*
WBC (103/dL), 10.35 vs. >10.35 44 vs.22 0.006*
Hb (gm/dL), 12 vs. >12 25 vs.41 0.872
Platelet (103/mL), 130 vs. >130 7 vs. 59 0.266
INR, 1.3 vs. >1.3 59 v.s.7 0.119
AFP (ng/mL), 9 vs.>9 51 v.s.10 0.287
CEA (ng/mL), 5 vs.>5 28 vs. 34 0.092
CA 19-9 (ng/mL), 300 vs.>300 28 vs. 38 0.001* 0.027* 2.091 (1.089e4.015)
AST Z aspartate transaminase; ALT Z alanine transaminase; Alk-p Z alkaline phosphatase; AFP Z alphafetaprotein; CA19-
9Z carbohydrate antigen 19-9; CEAZ carbohydrate antigen; GGTZ g-glutamyltransferase; HbZ hemoglobin; BZ hepatitis B virus;
C Z hepatitis C virus; INR Z International Normalize Ratio; NBNC Z non-hepatitis B or C virus; WBC Z white blood cell.
* A value of p < 0.05 was defined as statistically significant.
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noted that patients who had accepted treatment (Group I
and Group IIa) had longer survival rates than those without
treatment (Group IIb) (p < 0.001); surgery (Group I) pre-
sented better outcomes than the nonsurgery group (Group
II) (p Z 0.012); and surgery provided the longest survival
benefit among the three groups (p < 0.001) over the study
period (Fig. 2). Furthermore, analyzing 3- and 6-month
outcomes in separate and advanced-stage patients, signif-
icant differences were found in Group I versus Group IIa (4/
17 vs. 0/19, p Z 0.040); Group I versus Group IIb (4/17 vs.
20/30, pZ 0.006); and Group IIa versus Group IIb (0/19 vs.
20/30, p < 0.001) at 3-month mortality. Significant differ-
ences were also found in Group I versus Group IIb (6/17 vs.
25/30, p Z 0.001) and Group IIa versus Group IIb (5/19 vs.
25/30, p < 0.001) at 6-month mortality. Similarly, in
advanced stage patients, significant differences were found
in Group I versus Group IIa (4/11 vs. 0/15, p Z 0.022), and
Group IIa versus Group IIb (0/15 vs. 18/25, p < 0.001) at 3-
month mortality; Group I versus Group IIb (4/11 vs. 23/25,
p Z 0.001) and Group IIa versus Group IIb (5/15 vs. 23/25,
p < 0.001) at 6-month mortality (Table S2).
Discussion
Comparable with a prior study, this study found that most
ICC patients (51/66; 77.27%) presented with an advanced-
stage condition; only 10.6% (7/66) of patients were diag-
nosed in the early stages of ICC [8]. The study resultsshowed that 36.4% (24/66) patients died within 3 months
and 54.5% (36/66) within 6 months due to the silent clinical
character of ICC which delays its detection and results in
unresectable conditions and high recurrence rates even
after surgical resection [9]. In order to attain the greatest
benefit in clinical scenarios, two points were assessed in
this study. Firstly, the predictive factors affecting survival
were investigated, following this the benefits of various
modalities including curative, palliative, and no treatment
of ICC patients were examined.
In keeping with previous studies, the clinical parameters
including male sex, advanced tumor condition, lower al-
bumin, higher bilirubin, and higher CA19-9 not only showed
significant correlation with 6-month mortality (Table S1),
but also served as independent indicators which could be
used to predict patient mortality (Table 2) [1,8,9,17e23].
This was a logical finding as both components including
deteriorating liver function and progressive tumor condi-
tion play determined roles affecting patient’s result in
clinical scenarios.
Owing to the silent course of tumorigenesis, curative
resection fails in the majority of cholangiocarcinoma cases
and palliative therapy is the main treatment modality. The
aim of palliative treatment is to reduce jaundice resulting
from biliary obstruction, improve life quality, and possibly
prolong patient survival [24e26]. Of the various modalities
examined in this study, it was found that although Group I
(surgery group) when compared with Group IIa (palliative
group) failed to provide 3- and 6-month survival benefits in
Figure 2 Kaplan-Meier analysis of treatment versus no treatment (A), surgery versus no surgery (B), and comparison of three
modalities survival (C). A value of p < 0.05 is considered statistically significant.
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Group I still presented the best survival outcomes of each of
the three modalities over the study period (Fig. 2).
Although complications of chemotherapy and radiation
existed, Group IIa still presented better survival outcomes
than Group IIb (no treatment) in overall or advanced-stage
patients at 3- and 6-month survival (Table S2). This dem-
onstrates the benefit of palliative therapy in patients with
unresectable tumors. This finding supports previous studies
where chemotherapy and radiation were identified as mo-
dalities that prolong patient survival in cholangiocarcinoma
cases [9,21,27e29]. This finding also correlates with the
observation of higher mortality in patients receiving no
treatment (Table 2). With these findings in mind, it is vital
that cholangiocarcinoma patients receive a thorough initial
examination to ensure the most appropriate treatment is
identified [30,31].
In this study, ALP associated with biliary tract disease
showed no significant impact on mortality at either the 3-
or 6 month time points or over the study period; however,
where high ALP levels were observed they appeared to
account for borderline differences in mortality when
compared with survival cases [9]. Similar findings were
noted in clinical factors associated with liver conditions
including GGT and INR, as well as renal function and WBC
counts (Table 2 and Table S1), however, the implication of
these findings was limited by small case numbers in this
study, as well as other factors which were not accounted
for such as the effect of adequate hydration and infection
control in clinical scenarios. HBV and HCV are well known
agents for HCC formation and have also been reported in
the development of cholangiocarcinoma [32]. However, the
study findings did not show predominance in patients with
hepatitis B or hepatitis C when compared with those
without HBV or HCV infection among ICC patients (Table 1),
which could be from demographic differences.
Overall, surgery was identified as the modality providing
the best survival prognosis for patients. However, ICC was
only detected in the early stages for 10.6% (7/66) of pa-
tients due to a lack of specific symptoms in the early stages.
This meant that the majority of patients were not diag-
nosed in time for surgery. Treatment using chemotherapy
or radiotherapy was found to prolong survival of ICC pa-
tients with unresectable tumors. Better liver preservation,
lower CA19-9, and less aggressive tumor conditions were
also important factors. Highly selected patients and
genomic studies will help to promote patient survival in the
future [33]. We believe that the findings from this study will
provide clinicians with effective therapeutic options to
maximize health benefits in ICC patients.Conflicts of interest
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